Sylentis
Ophthalmic pharmaceutical company developing novel treatments for ocular diseases.
Check the tech stack behind sylentis.com. Find a founder email at sylentis.com.
About
Sylentis is a biopharmaceutical company specializing in ocular gene silencing therapies using RNA interference (RNAi) technology. They develop siRNA compounds to reduce the production of disease-causing proteins, with a current focus on treating dry eye syndrome and age-related macular degeneration. Sylentis also offers siRNA development services and collaborates with other companies on oligonucleotide-based drug development. Teams look it up for Biotech, MedTech, HealthTech.
Frequently asked
What does Sylentis do?
Sylentis is a Biotech company that offers Services. Teams look it up for MedTech, HealthTech, Drug Discovery. It is based in Madrid, Spain and was founded in 2000. Public records show about 61 people and $135M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Sylentis raised?
Sylentis has raised a total of $135M in funding. The most recent round on record is Series C.
Where is Sylentis headquartered?
Sylentis is headquartered in Madrid, Spain.
When was Sylentis founded?
Sylentis was founded in 2000.
What industry does Sylentis operate in?
Sylentis operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials.
How many employees does Sylentis have?
Sylentis has approximately 61 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.